ࡱ> &(#$%G dybjbjَ ,\]vvvvvvvFFFF8~\F>"kmmmmmm$Խȿv"vv vvk^^vvvvk"dvvk^, fFFyvPharmacology Study Guide Test 2 Analgesic Agents Ch. 10 Analgesic: relives pain w/o causing unconsciousness Pain: most commonly described as unpleasant sensory & emotional experience associated w/either actual or potential tissue damage. Pain threshold: level of stimulus to produce perception of pain Pain tolerance: amount of pain a PT can endure w/o it interfering w/normal fx. Acute pain: sudden in onset; subsides w/tx Chronic pain: persistent & recurring Somatic pain: originates from skeletal muscles, ligaments & joints Visceral pain: originates from organs/smooth muscles (superficial) skin, mucous membranes Visc/superficial tx = opiods Somatic pain tx = nonopiods Vascular pain: originates from some pathology of the vascular or peripheral tissues Referred pain: visceral never fibers synapsing at a level in the spinal cord close to fibers that supply specific subQ tissues in the body Neuropathic pain: injury/damage to peri nerve fibers or damage to CNS Phantom pain: removed body part (burning, itching, tingling) Cancer pain: many causes, i.e. pressure on tissues, organs or nerves, hypoxia, blockage to an organ, matastisis, pathologic fractures, muscle spasms, side efx of radiation, surg & chemo Phsychogenic pain: psychological factors that actually stimulates nerve pain impulses Central pain: tumors, trauma, inflammation of brain and may occur with any condition that induces CNS damage Type of FiberMyelin sheathFiber sizeConduction speedType of painAYesLargeFastSharp/localCNoSmallSlowDull/nonlocalized Neuron regulation: Conducting an action potential releasing neurotransmitter binding transmitter molecules to receptors Pain Gate Theory Massage to area relieves painlarge sensory fibers from peri receptors carry impulses to spinal cordthis causes impulse transmission to be inhibited & gate closed, which reduces the recog of pain impulses arriving by means of the small fibers. Opiods work in this way. p. 149 Steps in Junctional Transmission Synthesis: a transmitter substance is needed Storage: this transmitter must be stored until released Release: triggered by an action potential at the axon terminal Receptor binding: after release, transmitter undergoes reversible binding to receptor site Termination: removal of transmitter occurs PNS RX Cholinergics: either block or stimulate actions of Ach Blockers: muscarinics, ganglionics, neuromuscular blockers, cholinesterase inhibitors Adrenergic agonists (epi) vs. antagonists block or stimulate SNS Indirect acting antiadrenergics Neurologic Rx: patho of disorder is depletion of dopamine (inhib transmitter) i.e. Levodopa; carbidopalevodopa Epilepsy TX: reduce rate of d/c of neurons; prevent spread of seizures to rest of brain i.e. phenytoin; Phenobarbital; tegretol; diazapam Muscle spasm/spasticity RX i.e. analgesics (ASA), centrally acting relaxants (Diazapam) Opioid Analgesics (only 3 clinically useful, morphine, codeine, papaverine) Mechanism of action & DE Agonist binds to opioid pain receptor in brain & causes an analgesic response Partial agonist: binds to pain receptor and causes only limited actions Antagonist: reverses the efx of these on pain receptors Primarily bind to mu, kappa & delta receptors Many opiods have affinity for CNSsuppress medullary cough center Strong opiods for surgery: fentanyl, sufentanil, alfentanil (balanced anesthesia) Post-op pain TX: Morphine, meperidine, oxycodone, MS Contin long acting Analgesia: codeine (also antitussive) NSAIDS Lodine: dental Ibuprofen: only OTC NSAID Indocin: if ASA or Tylenol doesnt work Naprosyn: for tx of O/A (monitor effectiveness) Mixed Narcotics & Non-narcotics: Percoset: mixed with Tylenol Perdocan: mixed with ASA Darvon & Darvon N: weaker in action, analgesic, sedative? Vicodin: Tylenol & narcotic Stadol: used in MCH, pre-op, watch for OD, change in alertness, hallucinations NARCOTIC ANTAGONIST: NARCAN: used IV for immediate action, blocks mu & kappa receptors; reverses opiod works in mins, used when resp are below 10/R per minute, minimal toxicity CONTRAINDICATIONS: allergy, asthma, RT insufficiency, elevated ICP, pregnancy SE/AE: euphoria, dependence, tachycardia, ( BP, mental agitation, nausea, vomiting constipation, urinary retention, pruritis (due to his release), flushing, orthostatic hypotensionserious side efx=CNS depression which leads to R. dep Non-Opioid Analgesics (primary: Acetominophen (all drugs in NSAID class) Mechanism of action & DE Similar to Salicylatesblocked pain impulses peripherall via response to prostaglandin inhibition Acetaminophen: ! fever by acting on the hypothalamus; vasodilation & heat loss No effect on platelets, cardiovascular or respiratory system, or acid-base changes Fever, moderate pain TX NOT SURE IF THIS DRUG WILL BE ON TEST CNS Depressents & Muscle Relaxants Ch. 12 Sedatives: reduce nervousness, excitability & irritability w/o causing sleep Hypnotics: more potent than sedatives; causes sleep Sedative-hypnotics: barbiturates; benzodiazepines, etc. Barbituates First used for tx of insomnia & producing sedation; narrow therapeutic index Mechanism of action & DE CNS depressant ( works in the reticular formation Inhibits nerve impulse transmission traveling to areas of brain due to ability to potentiate an inhibitory amino acid GABA Low doses act as sedatives High doses act as hypnotics Cause enzymes in liver to metabolize drugs more quickly, which shortens their actions. Capable of raising the seizure threshold Used as hypnotics, sedatives, anticonvulsants & anesthesia for surgical procedures. Differ in potency, onset, duration of action Ultrashort: anesthetics Short: sedative-hypnotic Intermediate: anticonvulsant & sedative-hypnotic Long: sedative-hypnotic; anticonvulsant Long acting: Phenobarbital & short acting Pentobarbital (Nembutal) CONTRAINDICATIONS: pregnancy, significant respiratory difficulties & severe liver disease SE/AE: drowsiness, lethargy, dizziness, hangover, restlessness or excitement; affect normal sleep by depriving REM. Adverse reaction: respiratory depression; CNS depression Toxicity: activated charcoal, assisted respiration, interactions w/alcohol, antihistamines, benzodiazepines, opioids & tranquilizersmost are secondary to efx on hepatic enzyme system i.e. MAOI coadmincan result in ! anticoagulation response and clot formation Benzodiazapines (most commonly prescribed sedative-hypnotics) Mechanism of action & DE Depress CNS (hypothalamus, thalamus & limbic systems) by inhibiting stimulation of brain Receptors thought to be those of inhibitory transmitter GABA They do NOT suppress REM sleep or induce hepatic microsomal enzyme activity, so safe to admi to PT taking meds metabolized by this enzyme system Calming effect; controls agitation & anxiety by inhibition of hyperexcitable nerves Skeletal muscle relaxation Used in Tx of alcohol withdrawal, agitation, depression and epilepsy Tx is symptomatic & supportive CONTRAINDICATIONS: pregnancy, narrow angle glaucoma & other CNS depressants & coadmin w/MAOIs SE/AE: drowsiness, headache, excitement or nervousness; dizzy & lethargy Adverse efx: can lead to falls in elderly, also effect normal sleep cycle hangover effect Toxicity: confusion/coma; diminished reflexes, somnolence, syrup of ipecac generally used, gastric lavage Muscle Relaxants (needed for conditions such as trauma, inflammation, anxiety, paincan be assoc w/ acute muscle spasms) Mechanism of action and DE Work w/ CNS & actions come from sedative efx rather than direct muscle relaxationact on nerve transmission in spinal cord..enhance GABAs central inhibitory efx @ spinal cord Only ONE works directly on skeletal muscle: dantrolene Effects are a result of CNS depression in brain at level of brainstem, thalamus & basal ganglia Tx of muscle-skeletal conditions (spasms, chorea Involuntary dancing or writhing of the limbs or facial muscles, spasticity), such as MS, cerebral lesions, cerebral palsy or rheumatic disorders. Huntingtons chorea, ! rigidity in parkinsonian syndrome or pain assoc w/trigeminal neuralgia Flexeril, baclofen (aka Lioresal, Atrofen) for TX of hiccups CONTRAINDICATIONS: severe renal impairment SE/AE: euphoria, lightheadedness, dizzy/drowsiness, fatigue, muscle weakness& short lived. Dantrolene = hepat tox Toxicity: NO specific tx!!! Supportive therapy CNS Stimulant Agents Ch. 16 (stimulate a specific area of brain or spinal cord) Amphetamines: CNS stimulants that elevate mood or euphoria, ( mental alertness and ( capacity to work, ! fatigue & drowsiness Analeptics: CNS stimulants that have generalized efx on brainstem & spinal cord (( response to ext. stimuli) Anorexiants: suppress appetite Cataplexy: abrupt attacks of muscle weakness & hypotonia triggered by emotional stimuli such as anger, fear, surpriseoften associated w/narcolepsy Narcolepsy: syndrome charx by sudden sleep attacks, cataplexy, sleep paralysis & visual/auditory hallucination Seratonin agonist: new class of CNS stimulants used to tx migraines stimulate 5-HT1 receptors Sympiomymetic agents: another name for CNS stimulants (aka amphet., caff., cocaine) Oldest known: cocaine & amphetamine; also caffeine Anorexiants for tx of exogenous obesity; appetite control via suppression of appetite ctrl centers in brain Analeptics: generalized efx on brainstem & spinal cord Amphetamines for tx of narcolepsy & ADHD by ( the amt & duration of nore and dopamine CONTRAINDICATIONS: marked anxiety/agitation, glaucoma, tourettes MAOIs p276 SE/AE: speed up body systems; ( CV, hypertension, restless/nervousness; get VITAL SIGNS for baseline Assess for OTC! i/e. ephedra/ginseng Adrenergic Agents Ch. 17 (drugs that stimulate the CNSmimic nore & e) Adrenergic receptors: receptor sites for the sympathetic neurotransmitters nore & e Adrenergics: drugs that stimulate the SNS; they mimic the efx of nore & e Alpha adrenergics: further classified into alpha1 & alpha2, differentiated by loci on nerves Autonomic fx: involuntary, result from physiologic activity of the ANS. Occur in pairs of opposing actions between the SNS & PNS divisions of the NS. ANS: controls autonomic bodily fx. Consists of PNS & SNS B-adrenergic receptors: located on post synaptic effector cellsthe cells, muscles & organs that the nerves stim. B1= ( B2= smooth muscle, bronchioles, arterioles & visceral organs for tx of asthma/COPD Catecholamines: induce SNS response, ( CO & ( HR and ! GI; either endogenous (nore & e) or synthetic (dobutamine) Dopaminergic receptors: when stimulated by dopamine cause the renal, mesenteric, coronary & cerebral arteries to dilate the blood flow to ( Catecholamines: specifically metabolized by two enzymes: MAO (monomine oxidase) & COMT (catechol O methyltransferase) Noncatecholamines: structurally dissimilar & have a longer duration of action than the endogenous or synthetic cathechol Adrenergic Drugs (cause biologic response similar to SNS catecholamines & noncatecholamines) Mechanism of Action & DE Rapid onset/distributed widely; systemic/local efx (alpha tx hypotension, beta tx bradycardia) Bathe the synaptic cleft (area between nerve & effector organ) Bathe the synaptic cleft (area between nerve & effector organ) Work by direct stimulation, indirect stimulation or a combo B2-adrenergic: bronchodialator = epi, ephedrine, pseudoephedrine Used for tx of asthma, anaphylaxis; CPR, hypotension/shock; allergies, eye exams Alpha agonist: vasoconstriction of arterioles in skin, kidneys, mesentery A1-receptor: pupil dilation, nasal decongestion, mesentery A2-receptor: work on presynaptic nerve terminals: cause release of nore and ! BP Dopamine agonists for tx of parkinson s disease Epinephrine for tx of bronchodilation & potentiate anesthesia Dobutamine ( CO; used in acute CHF (nursing indication: monitor BP, RR, inhalant usage) Noncatecholamines: longer duration, given PO, works directly & indirectly for tx of hypertension, congestion, asthma, bronchitis Epinephrine for tx of bronchodilation, Albuterol (B-2) for tx of bronchospasms Ephedrine: activates both A & B, similar to epi but slower onset, longer acting, less potent for tx of nasal decongestion, bronchodialator, narcolepsy CONTRAINDICATIONS: severe hypertension SE/AE: alpha-adrenergics:h/a, tachycardia, palpitations, dry mouth. Beta-adrenergics: mild tremors, h/a, nervousness, dizziness, unwanted side effects on CV syste, ( HR, palpitations Toxicity: stop drug quickly Adrenergic-Blocking Agents Ch. 18 (interrupt or block stimulation of the SNS) ! nore or prevents action of cholinergics& alpha blockers, beta blockers, autonomic ganglion blockers Alpha blockers: interrupt/block stimulation of the SNS which leads to: Vasodilation, ( BP, constriction of pupil (miosis), suppressed ejaculation Mechanism of Action and DE Have a higher affinity for a-adrenergic receptors than nore & occupy the receptor site before they can ! response to stimulation of the SNS effect depends on agent s selectivity for certain tissues/cells in body (i.e. by blocking fight flight/allowing breed/feed= uterine contractions, GI, bladder) Ergotamine for tx of migraine headaches by constricting blood flow (a/e=orthstatic hypo; fatigue) CONTRAINDICATIONS: peri vascular disease, hepatic/renal disease, coronary artery disease, peptic ulcer, sepsis SE/AE: orthostatic hypotension, tachycardia, vertigo, watch VS, chest pain and avoid alcohol/caffeine.most severe interactions are ones that potentiate the a-blockers effects Toxicity: syrup of ipecac or gastric lavage, then activated charcoal Beta blockers: compete with catecholamines e and nore B1 = heart ! myocardial stimulation, ! HR, slows conduction of the AV node, ! myocardial O2 demand B2 = smooth muscles contracts (i.e. bronchioles) and airway narrows ( peripheral vascular resistance Mechanism of Action and DE Comepete with and block nore & e @ beta-adrenergic receptors, then SNS stimulation is blocked For tx of hypertension, ! cardiac output: Atenelol B-1 blocker, second-step antihypertensive: Lopressor For tx of angina, hypertension, MI, onselective blocker: Inderol CONTRAINDICATIONS: uncompensated heart failure, heart block, bradycardia, pregnancy, severe pulm disease, Raynauds disease SE/AE: Acute withdrawl can cause worst effects (rebound hypertension); ATROPINE for crisis; hypotension, cough, sleepiness, bradycardia (AV block), CHF Autonomic Ganglionic Blockers: inhibit Ach, prevent or ! impulses transmission in ANS; used in emergencies to lower BP (antihypertensive) Given PO, not too stable, uses are limited and not very safe. Pt must be carefully assessed frequently Cholinergic Agents Ch. 19 (promote action of PNS & acetylcholine) Ach: neurotransmitter responsible for transmission of nerve impuses to effector cells in PNS Cholinergic agents: stimulate PNS Cholinesterase: breaks down Ach Direct-acting cholinergic agents: bind to chol receptors to activate them Indirect acting cholinergic agonists: make more Ach available at receptor site Muscanaric receptors: cholinergic receptors located postsynaptically in the smooth muscle, cardiac muscle and glands of the PS fibers & in effector organs of the cholinergic symp fibers; can be stimulated by alkaloid muscarine. Nicotinic receptors: cholinergics receptors located in the ganglia of both PNS & SNS; can be stimulated by alkaloid nicotine Cholinergic agents Tx of smooth muscle of GI/bladder & mgmt of urinary retention: Urecholine Tx for intraocular pressure (!) & mgmt of glaucoma, MG: Pilocarpine Anticholinesterase agents: inhibit destruction of acetylcholine; short term & reversible action Absorbed readily from GI, sq & mucous membranes ( effects of Ach, reduces intraocular pressure, stimulates peristalsis & promotes muscular contraction For tx of glaucoma, urinary retention, paralytic ileus, MG: Prostigmine Cholinergic blockers: (block the actions of the PNS) Mechanism of Action & DE NARROW Therapeutic index!!!!!!!! compete with Ach & cholinergic agonists @ muscarinic receptors & increase SNS efx Tx of spastic conditions of GI/urinary tract; asthma, parkinsons (ach short supply in parkinsons pt), motion sickness Txcan stimulate or depress CNS, depending on doesbradycardia, spastic GI, asthma: ATROPINE ATROPINE primarily used for CV disorders i.e. dx of sinus node dysfx, tx of PT w/ symptomatic 2nd degree AV block & adv life support for tx of sinus bradycardia accomp by hemodynamic compromise Know the next 3 drugs only as chol. Blockers for test Tx of parkinsons: 1)Cogentin Tx of peptic ulcer, preanesthetic; reduces arrhythmias: 2)Robinul Tx of motion sickness, ! salivation, amnesia, euphoria: 3)Scopalamine CONTRAINDICATIONS: GI or GU obstruction, bradycardia, defects in cardiac impulse conduction, hyperthyroidism, epilepsy, hypotension, COPD, parkinsons Toxicity: sludge: Salivation, Lacrimation, Urinary incont, Diarrhea, GI cramps, Emesis Neuromuscular blockers: disrupt neuro transmission; do NOT cross blood-brain barrier Tx to relax smooth muscle, redu ce muscle spasm, manage ventilator PTs Neurotransmission: impulsenm jctrelease of Ca+Ach releasedepolarize & Na+ entersresult: muscle contracts Nonpolarizing blocking agents: produce prolonged muscle relaxation Competes with Ach; rapidrelaxes/paralyzes skeletal muscle Tx adjunct to general anesthesia; minimal histamine releasing efx, doesnt ! BP, causes ( BP, HR, CO: Pavulon Depolarizing blocking agents: Action: short term muscle relaxion (i.e. intubation), metabolized in liver/plasma A/E: apnea, CV alterations Tx for ventilated PT, ultra short acting skeletal muscle relaxat: succinyulcholine Acid-Controlling Agents Ch. 49 (neutralize acid, or inhibit overproduction of acid) Hcl: secreted by the parietal cells & maintains stomach pH of 1-4 Pepsin: pepsinogen converts to this, secreted by chief cells in stomach Antacids Three forms: aluminum, magnesium & Ca+ based Mechanism of action & DE Stimulating mucosal defensive mechanismsstimulate mucus, PG & bicarbonate secretion from the cells inside the gastric glandsprotective barrier Tx for hyperacidity from gastritis, PUD, pyrosis Bicarbonate buffers acidic properties of Hcl Neutralizers mixed w/ aluminum: Mylanta Neutralizers mixed w/magnesium: MOM Neutralizers mixed w/ Ca+: Maalox & Tums CONTRAINDICATIONS: severe renal failure or GI obstruction SE/AE: diarrhea, renal impairment (i.e. mg levels = toxicity) constipation, interactions w/other RX, can change absorption/excretion of other drugs H2 Agonists Blocks H+ secretion from parietal cells by binding to receptors; ! but do NOT eliminate acid secretion Mechanism of action & DE Blocks acid production by blocking parietal cell secretion Tx of PUD, GERD, esophogitis, upper GI bleed Zantac, Pepcid CONTRAINDICATIONS: very few; minimal CNS effects; h/a, lethargy, depression AE: h/a, NV, diarrhea, confusion PPI Mechanism of action & DE: Binds to the H+/K+ ATPase which is responsible for last step in acid secretion from parietal cells More effective than H2 agonists in their inhibition of acid secretion TOTAL inhibition of acid secretion Prilosec (nexium, protronix, acphex) CONTRAINDICATIONS: long term use a concern; predispose to GI infx SE/AE: not many! Sucralfate Mucosal protective agent, acts locally Mechanism of action & DE Binds to surface of ulcersdisassociates into aluminum hydroxide & sulfate anions. Tx of PUD: sucralfate (carafate) SE/AE: may affect absorption; causes dry mouth, some constipation/nausea Antidiarrheals & Laxatives Ch. 50 Adsorbent: AD agent that acts by coating the walls of the GI tract, absorbing the bacteria/toxins i.e. Kaopectate Anticholinergic: AD agent ! tone of muscle in intestine and ! peristalsis Bulk-forming laxatives: adsorb H20 into intestine which ( bulk & distends bowel to initiate reflex bowel mvmt i.e. Metamucil Cathartic: any substance that causes emptying of bowels Emollient laxative: stool softener/lubricant laxative works by ! the surface tension of fluids resulting in more H20 & fat to be absorbed into stool & intestines (lubes fecal material)& i.e. Surfak & Colace Hyperosmotic laxatives: ( fecal H20 content which results in distention ( peristalsis & evacuation IBS: periods of bloating/flatulence/diarrhea alternating w/periods of constipation Laxative: promotes bowel evacuation by ( bulk of feces, softening the stool or lubricating intestine wall Opiate: narcotic based AD agent that ! motility of bowel & reduces assoc pain w/diarrhea..i.e. Opium tincture: Paregoric (onset 1 h, duration 4 hrs) contraindicated w/ETOH, resp depression, barbs, tranqs OTC=, lomotil, OTC = immodium Saline laxative: a salt w/one or more ions that are poorly absorbed from intestine..the na+ draws into the intestinal lumen Stimulant laxative: (irritant to intestinal mucosa) agent that stimulates mvmt of intenstine by stimulating nerves that innervate the intestine which ( peristalsis activity in the intestine i.e. Dulcolax (can cause constipation, used for pre-op exams) Antiemetic & Antinausea Agents Ch. 51 Induce vomiting by activating CTZ center; irritate gastric mucosa Neuroleptic agent: a drug that prevents nausea/vomiting by blocking dopamine receptors in CTZ & may also block Ach; i.e. Thorazine, Compazine, Phenergan, Reglan Anticholinergics: work by binding to and blocking ACH receptors on vestibular nuclei (labyrinth) Tx of motion sickness: Scopalamine Antihistamine: inhibits action of histamine, some prevent nausea via inhibition of vestibular stimulation (H1 & H2 receptors) Tx of motion sickness, n/v, allergies, rhinitis i.e. Meclizine, Antivert (antihistamines w/antichol. behaviors) i.e. Dramamine (low SE), Benedryl (ltd use d/t sedation), Tigan (post op) Seratonin blockers: block Seratonin receptors located in GI tract, CTZ & VC for tx of n/v severe nature (chemo agents) i.e. Zofran Prokinetic agents: block dopamine in CTZ tx for delayed gastric emptying, n/v GERD: i.e. Metocoopramide, Reglan, Clopa  INCLUDEPICTURE "http://images.google.com/url?q=http://www.brain-trainer.com/images_admin/pns_sns_sf.jpg" \* MERGEFORMATINET  Review (from Rick) CNS drugs: dep stim, sedative, hypoticknow the difference Different RX i.e. phenobarbitol, what meds NOT to take with Stimulation of CNS system, indications, why stimulate someone? CNS stimulation, what nursing dx you would have Imbalanced nutrition Ritilin, indicators, responses when child takes it: positive & negative Clinical manifestations of adrenergics & cholinergics, SNS vs. PNSknow the GI fight/flight how it effects pupils and other effects, bronchodilation/constriction Efx in bronchirebound efx with one of the typesafrin nose spray B-blockers, know S/A & A/E.what do you do? Complications of certain heart changes, pulse, HR, what does nurse do? Call MD? Prioritize. Atropinewhy do you give it? What conditions exist for this drug? Sjojens syndromecauses changes in the way you salivate: EVOXAC Scopalamine: know ID the B-blocker Synthetic derivativewhat does that mean? Does it work as well? Define. GI meds. ID this disorder and tx by this med Tagamet & Cimetodinesome things that a PT could do that are CONTRAINDICATED Laxativesknow different types, stimulants, emollients, how do they work, what do they do? GI raglan, zantac Classifications of antiemetics, Why would you use one vs. the other in the way they are chosen to be used H2 antagonists, etc. ! of acid production Define: iatrogenic (disease arising from complication of med or surg intervention) , tiatrogenic, antimicrobial, disinfectant PAGE  PAGE 1 ;Dpt267@!  &    ? F ~  CJOJQJ6CJOJQJ jUmH CJOJQJ CJOJQJ5CJOJQJ5CJOJQJN"#;p2n  $ & F & F"#;p2n      $ C ^  C ¼                                                  2     $ C x & F$Q$$l trz 4XC ^  ? ~   C iK & F  & F & F Gi#@JK\]*@OYav~3IQ4^_45h~TVIR}65CJOJQJ CJOJQJ 5OJQJ j6CJOJQJ6CJOJQJ5CJOJQJ *5OJQJ CJOJQJ5B*CJOJQJG iKF~@7Yv44h&VI}'Y b $=n3\^  !!b!!!!""i##4$k$$& 'b'"(Q(R((.*+F+7,     8    ZKF~@7Yv44hh & F8 & F &VI}'Y b $=n & F & F0 8 & F 8h & F0 867 $)=Inr3\^|~$ ' !!""###D#g#i####$$$>%&&&& 'b'!("(Q(R(Ľݵĵݡ CJOJQJ0JCJOJQJ0JCJOJQJ>*CJOJQJ6CJOJQJ 6OJQJ 5OJQJ *5OJQJ CJOJQJ CJOJQJ5CJOJQJ5B*CJOJQJ6CJOJQJ6>*CJOJQJ CJOJQJ jLCJOJQJ13\^  !!b!!!!""i##4$k$$& 'b' & F0 8h & F  & F b'"(Q(R((.*+F+7,,-Y-Z---0...;/`/a///G00:1s11 & F  & F & FR(n(((((((((((**.*B***++F+X+7,A,,,,,,,------\.].....:/;/a/z//////////0G0L0M0X000B*CJOJQJ5B*CJOJQJ6CJOJQJ CJOJQJ j6CJOJQJ>*CJOJQJ CJOJQJ jCJOJQJ CJOJQJ5CJOJQJ6CJOJQJ5CJOJQJ=7,,-Y-Z---0...;/`/a///G00:1s11|2`3<44,5556A6666N777H88$99k::Q;x;<2==E>>>?J@A&BBCCDzEElFF8@88:9<9j9 j5B*CJOJQJ5B*CJOJQJ6B*CJOJQJ5B*OJQJ *5B*OJQJB*CJOJQJ jB*CJOJQJ>*B*CJOJQJ jYB*CJOJQJ5B*CJOJQJB*CJOJQJ91|2`3<44,5556A6666N777H88$99k::Q;x;<2==E> & F & F j999k:w:::::P;Q;x;8<:<^<<<0=2=4== >E>S>T>@@AA&BBECCCCDD4D6DDDDD8E:ExEzEjFlFFFFȽȶȧ⧌اȶ⧠5B*CJOJQJ jCJOJQJ *5CJOJQJ CJOJQJ CJOJQJ5CJOJQJ CJOJQJ j6CJOJQJ6CJOJQJ5CJOJQJ5B*CJOJQJB*CJOJQJ5B*CJOJQJ56B*CJOJQJ3E>>>?J@A&BBCCDzEElFF*CJOJQJ5>*CJOJQJ jCJOJQJ 5OJQJ *5OJQJ5CJOJQJ CJOJQJ56B*CJOJQJ6CJOJQJ5CJOJQJ5B*CJOJQJ CJOJQJ5B*CJOJQJ9LL5MNNNNNPQnQRgRRRR(SSSTTURU`VXXsX & F% & F% & F& & F( & F$ & F#ORTRZReRgR|RSSSZT\TTTTTUUJUQUVVFV\V`VWWWWWWWWWWWWX X XXXXXZZZZ6ZFZ[\ǿﰩ jCJOJQJ *CJOJQJ *5CJOJQJ>*CJOJQJ CJOJQJ5CJOJQJ CJOJQJ>*CJOJQJ5>*B*CJOJQJ5B*CJH*OJQJ *5OJQJ5B*CJOJQJ CJOJQJ5>*CJOJQJ2SSTTURU`VXXsXX(YkYYFZZ\[\\V\\\\]/]]]^F^j^^a_n_L```Pana$b(bBbbbc3ccccc$dEddddd$e`fZggfi,jjk3lll;m7n^nnAoooEppLqqqqqqqq3 3 2 2 1 . - , , + * ) % % RsXX(YkYYFZZ\[\\V\\\\]/]]]^F^j^^a_n_L``` & F- & F, & F, & F+ & F* & F)\!\U\V\Y\\\\\\^*^>^E^F^R^f^i^j^v^^^^^^^^a_n_``DaNaPana$b(bcc3ctcuccc/dDdddde$e3effDfFf`fhfjfxfzfffffCJH*OJQJ5>*B*CJOJQJ5B*CJOJQJ CJOJQJ5B*CJOJQJ6CJOJQJ 5OJQJ *5OJQJ5CJOJQJ CJOJQJ5CJOJQJ@`Pana$b(bBbbbc3ccccc$dEddddd$e`fZggfi,jjk & F2 & F1 & F. & F-ffFgZglgggggHhJhi8iFidifi~iiiiiii,j2jjj k"kkkkkClLlllllllll;mDmEmMmmmmn7n^nnnnnoAoQooooooDpEpzpppppppppǿ5CJOJQJ CJOJQJ>*CJOJQJ CJOJQJ5CJOJQJ5B*CJOJQJ CJOJQJ jCJOJQJKk3lll;m7n^nnAoooEppLqqqqqqqqrrrrrr & F3 & F3   & F2 & F2ppqzqqqqqqrrrrrttxx(y.y0y2y>y@yByFyHyTyVyXyZy\ybydyŽ0JmH0J j0JU CJOJQJ *CJOJQJ jU5B*CJOJQJ CJOJQJ5CJOJQJ CJOJQJ!qrrrrrrrrrrrrrrrrrrrrrss]s^ssssstttttt[u\uyuzuuuuuuvvMvNv{v|vvv%w&w8ww*x,x(y*y,y.y0yFy\y^ydy5 Crrrrrrrrrrrrrrrrss]s^ssssstttt & F5ddttt[u\uyuzuuuuuuvvMvNv{v|vvv%w&w8ww*x,x(y*y,yd & F5d,y.y0yByDyFy\y^y`ybydyh&`#$d 1h/ =!h"h#$%n#thMhnmPNG  IHDR3 PLTE ]]] bKGDH cmPPJCmp0712Om"{IDATxolG૫68IB8Il(!C8|@^&-^Y`{mxG$v[eFL{ ȭ A.[ N,q%mFft͌{U٤;SD]WU{UDw@:k͇Fdydlhymb^+M l*51l4nN4kBί;U;z2kwey=Z(˿Qqj~א06 ("T7oTk2uj)_C|KPXiO1n .?shHkJҟJ+Ϡ 3bSg| jN>$TΈ>*Sæu =jiͧƐl_ndOH0?]z`1ńh*^J|gE;%iYblmYY-^8klʽ_njώDp3N^WB 'i9BVڎة|NH#cSոxHvW?ދVs/FUߟ]ꄺ"R@v4(,bK'W?uu]Hֆ!6m+T _UaX jhG/-Q5Df)~ã#CҺp+fSK[Ta4ۿ_\GW C$5ϕV yBmG{x"4JY]M g}b| lS9]Un.EVzTSiRPJ[]p-Rc")khS?NrMuk>GHzM& 'Ө뗂2QZ":l~Ut ll%xEONO(**FC*]GiO;?(]h-glOPMtg]4*PN1]8 ЏA:BSu("eUf8tAdR&tܦr)TLXsC6ugԽ7M}8mSTՁ}6ku.LdK i/S&YEjnHyf!F`/b >ceRs3솖7To^T'K%2j oţrId==Vr?E`Mq D 5֞YDu~ړm޷oaFٍȰcUyPwF\w)B!mzw4=X'=kVx:խbU+#6kSۗFӱ  g2_n/ hpՈ;?}Ow!B߈ZWCCsmE=?7U䃉EJ 9]mt&| m1z+͎k_֏l v_5Zbq|MIl#+cy"JeuH(͸^KOpަW ~Ӎ{h_z.`{H㭎 csgdv"ML&N MN KIq'o]=uUЊ_-_^҄W?RI |ʊԊ(HE:oQ\+EY-=bS:z2QٌJ@!RY!iaqM;YE E9I]gq#j ;a̋ %܉)[:%ĤHL !? Mzsc5)^{ .zu9G>J+tR5T(+jl`O0HBd jV]iP BNxiD)H[^+7ܣԔDŽїjRJ(U%Te+$ΰԗ|pKH*&Rxf2ܧXz˸V{ 7YVotZR؅8˟M\^ IkmصPPlReRY}Mm.t?U]& ^4 hwAw!s]G\L3eYVq6]f1(+le` bE:]%^C aBATDI2Ur>xs-53(TY5E%9ʐ-5{r=oRb?YW(\Uh< s\$vChWjotڊ'3\ v$?#?&VVM͓G!6r >=8r̐00/ǀ:Rc-؞UjsEu/zדU|Pw"{a>2lK1'FPXz91dX0@:E4T y=#nȓ#4QGEP}\5޵+DYK^!4BnRiLͤ<'m&Ђ>QJmXT m.t_Ee{COUp ˯Q"8큡"djdr鬡ڋLk"}Ve>r#jq_F7JT$* Ĕ: &X?fN_C_ fOʫ !j3Ӕ.#s|?4R`xZɣd.4l|u 3Jbڢ'w3Usۼb&'|G9Tt-\ BuÈqz3ˈ<a>yyq. 9D{O~ΩD])-Bd Wu'b=~j giA[~BI#b3T<>=1;H_`rHk n1MUTr@()7PV%+} dU+D]ELC/=xO_PI IRtZD Mj%i>aVPW[uw6^c+8BVY5!eyĴoA`SDK8[lU%{aCMfЋ~)֭2*=>~uzh@뷩VU[ 5A]Vb&B^hx=S:(H%YΝKĦ]+ !t AQ%{|&u!uD&{RTU kMr jTy(9gzYΪ2If|UcިO\y 1w1EdBb!7uKj} ZRs֛y:UA'߂CT-Nq=T1?y Tp٨Zݱ>ym5{R98ΙRoʾtXNV(,oR w}7iA[ԛCug N@AnTt< io{oi2gcU?JW,*E֑'nY &pݑ7Dm}nɹlP)TJd'j+5Ԥ&:ghU 狅)i03.5dnt;60*.Uމl27A@įdgAṹG)tdInqkja_JJGVI.UHE6 mǐs8w?͸ $iɉ :Nۦ7bm?:}=#TQ>z#$-V@B˺^g*$4g0`uRYjX~; [T ;|Bn>^@ݺf߱e W:)c*WIU[M'E2ixl(IZIsNn>P9=q;@*.qGrڡHQĿCnTw)u̩Vuq=smNN;Tᇣjh=Yu(vc7n1ԷCUgTh] k#0E(oiX=WhjPg C啴 (g$` nTM8gPԓe2@T*,^UQTDϿ*e.Ws~)i- u '^Lyp5W8*9GQjt?Ä:P)sw$`y ) eznwLնki]K*-AwE,ҫh"662uR9; j,TŽ6Zy{:"FR%msϚ7'7ʌ ,s9hJ .6\*֏?9B )zSc̅k0nE(+1wO5M5W7C}̈x9bbgD2ikҫnOjH5M{0-]^NYY+o瑙X,ъ-ΪZ)e)2;#z, ў&y~j)Nԥ:N;gyӟIÔR4ܚX0M*SAጙә CMA1I7ZٮwᗡNM˃ Y"gE1pO$C%2HK={.{C~^s],N7Y1#3T2jP\?WT|ځ2M0JRˇG&K ƺ]W`(Tr+"*.v`d P!œs}i讶dK9zp /Njb>jD1 ҜbLpW^mGd3Dیwt!ˆ?jU'gox6)3T]n#Cꆐk NE;yuh8yFz ՍM 'eUn !IxJTLb膛G3BuL`u23oMtΑ/heS*xTfdk$)帮vnr|<ҨM}7]΂5.ja]m$֡ږ7auD5 ;UN߾yuz<$OJQX>xwF;Rp ģ]Iv{K]z /ӧ#o yۚ?@B㰥f|C0 ]sƮh'slQyd,Ja$}3b]h(v䙙 EpN5Z<7K% (fq?G_:0~HQe YV,^-] 5_׸dO+)ذH?Qݬ&C9JC!w^/[bD1'dQu`|ljo:`e) c@ ;:D5]F;>jo(qZܪ*YƊ"TV{{8C,Z5ϧv d2<LN=WD2.SjHJLH ujԡZsj%o^Vj >j'&ghXZ7&7,_7oGgzvQx (h*J>qH^ztyHF"duGW2Vey|opW_GE2TW#i? pǑ P 8A>c߷02]}gҢumPJ Yf #^Q'( =?p=p̝¨%(r%q.+3(*j`ʮ] AE feX vٛ<ՎXCImu*$7XtneNf#cq%0FRK"稒,p>5]D?Q;|3HD㠩+(NdmrEU^dŴDWڪMAǧu,D3yMޭaũ%do-52rrxX#Jdj*Z 5ts  yriz 1hO7k:.ʁ!.7ͳ{Nfd4%"ĹK )bKrA'aov/' ʮm+M5Bq2w'!ft0(;պ,7\XSXGG~B3@ys2N ;N`a{n&3kJ,,{)^k7a`AQ Ȍ<BzBǡЖ'@9i;[St=д\^|1A@NҘ'S%W57k^ A/f15Zi'|7Ü_ND)!>E.JBӎ~2’Aóo ր Jn;&aZ{6*voPVZ"'H؇E+t<׾~o"{䞶1!{9GUr#V A5dOp k+Dq{k8#}dOt%-f!I:qtfu:tt~=[TB8*̆Davl d 2ջt*(yZ0I K:~w*QjzdOҶqBEla} r[m{S3(*" bTف̿mKLNvk3I(/?86(ȉ G[>~#e҂BR vπXPԬZ IZRE+BSg/ʗ8fLx鍞O6_[( IENDB`=mDdZ  S 6Apns_sns_sfRlEK}0􀰲|klD0FclEK}0􀰲|JFIF``C     ""$$"".....0000000000C $$)# #)&($$$(&++))++000000000000000S"Y  !1"AQa#25q3BRST$Ubrt4Cs%&6DEcde11!2AQaq"3BR ?:H܄Hb좵I Gt?+ WDWc0SO2^pe}JSO2.R>dZ-X3CqZSJs'JOP: q9RO 7|ٕםbS8Nn!mIm*XqJ^er*HؙKnJۋ EAiH?̯w2mW3x)mĸ麇WյNb>c*f7'_f@aw oW^V?3EK!w 8pɭ\YCK@p7 BJt+O8>%JB#.j{Gb %Ѣ S8vF0NE"Aʾ2PXQ8CV*9UeǔK:]McJfb4hsASJN9/nc:I5σaOvrv J,Pk1KڝiIȥ\Ұoo]}#sz̛eVU$Kʇ}iJe$QN:pwXS.R  #?G6OUFi8f^5bRJn=⧾`p_S 8 a.kAg;u (ïÔYm(CƵgJˋKXç+HJUւybWxfUb s'EdOC8CڜP:9Dym+ASn_Q9|&f*6C>k:0~6:@~)3ԛ+X+. X^I/]ԄfBzx5Ywi[H+DBm{ G:MlT+q) S\5M6=z(hxћʕm^'28V7oڒte(%/@k0s"ooܷ7Yim-4,$X+JJ{O|**=⧾`px^MxoWj^=z=ɶ´^л!)Ɛl66 ڱ#id _RbdecknoQd;{[\hqy$(yW]7tp%"=phrWeb m )yd`Rv`M(Par+*RE4Z&,d#t%-Ԯ5k}{ښqGOQ+C>G|N{k(˅'VVI_m+83caυn^-Ή ֵ+C\`pNNhH5qRžVE[W,>(!?X Ȟ4ݔUzo#\aw u% )؎ 9e?XW^'m/qpJ?D#,Ī vTZpOK~A@VISЕuS'g=v,u.Ar5JIꃱ`\i9ĄݽNTT:.J/f@ʛh8U$~PGq27.%VK~;zQdsp2mƎ6msF0# 9-iQ1Bf[BP뎶3fC{sgQ5BCvߜJP5ݴoXV+B׽YkTe%ZkXanb6!ABҀ▒)m|r K+S{KemKT%)X|Skͭ}3PP5F|KD-6m칞^)^uo; #W)sgy9I CJ-;ħ6uG'Aqb1yIɾQwD=IYCb钟퍍Ӎ%]5F*uk1E/rUoپb7z^q➕=Q9Pݞ,?_CL'by^!̩U I Ƀ Z[1X">)wb1qC/a?K?F2ң1+r-4\տ\)fS%4*= U8Vi9%VCb##Twvh_=&zåk\IBwl^j"tS#4y"d:oˏea=.JqP`qgr;\ݘ4_%i !Jʲp:IĝL Wzk<,̩{1JRRQ2ARوjLf{3)+)ē,?ٵEq08n!,TJ[%V=.gu)э”ZS'D[[կ>YT*Nn"*!Y=@yqL0dZfAG;A؜&!s${ԅU푓OKTWP[ Aӆڵ`l aHSܔhM@7S 8 xXs^=ڤ׏urm*TR@)T1%2>ֵ骘(͈= ,9d]^54q컶*ttmn1IO7XZŷ@Il~: #Ec*DWQq%ED2Wn zT7ɡHs{`"ed[kq{Զ;*o/M2%S=Mro 9tjRz6lFp~΋+zT~&NU# gxr84*GyrU|#ƽ.6%GBYH?E` /99V㍩IrvC6hn3X!%.v.eI RVTZ#J`/:SmҮnd)hKE\uG qɁw\koeT1\ Z[Z\s18y HCjq(Jwmnl,u^6kZcut$uVU\i41?jf]@u Yk~wܳJKWN*mskGW`+ř ٽ PW6_-vrbHX5 C![̞Ts95B 7׺IFB6XGXNd״5X|/O8q[>ԬhkAu|D :~+i)diKM!JGUt ÎjN-]Ur$%2iWOXG{jbb\ U*>?-~?J(v~D;%R@77 JpxZwJ~hPݠCT}t1I폙#)RUI4rl:eM{@yy*pmU1 ai%c@X☛"!HnBUōֵQfGpӍHĶڢkj5 8NԩP5=*T *Tq=~?XUW?z5]MxoY& SSk1HgodrWc7=yrDVt[ wj6Q&-9HֵV[kK8%\6/QTS@ d d-Za $EYsE{*{eu\җs>J1)?r`/.l%'7N(_c 6*C3S2j[kÝÍwm$gS+xO0$|(56i9 *(w.V8(|uGc"GfLe:KpGW-ZCJ] jҳROT[.ԐGLP]CsfU(ZNgZq0i_511aXJcp߭1q&  ? Ede-2H"mV>JYT*j5AbF}X6]TAZlz\ @P͛1ߟhEvÑe䑽GNǹAYpd-wnv)'Rqhxy Ѕz-)N?[~l0<)=q`1B0{#`lG˟w;:9'NpCsUlYJh$tҹyo;OãVs_Wɶ3O!czݣڏ9 Ut%j~1l#c:~j?6|UY_ŧDq2yH C| n6)M_i6y谐Wnh6"Jo E| ?vn_巤-Q ʧR :t²jy^FK/bj7ꢻeFDCjQCm R:Y2c,e2ʫÀ[[ihb'dU6lۥIUHB_Uw): k%z֟C[qs#TöiUzy'#~Yڜe3 >~!(ٹR,tHм?nLd0m7xԒF/nn[qh [wݨJoUfpQҰ!1fddh|up;ppqT-nlBj7 UATcx#Fs%$3^[uЄE;tQ#>b-c¢â@ xF:z9`AFH~rO$[pvSbx4hLN\(\qj jvuӌȌc߶Pi (#Nv讈]i!4)Q+OmAȷҁ){{IG<6d[0!D{_tnaj?@7S 8 xXs^=ڤ׏urmTCLl:@= nv3 =$6bGkze6~,)COHmFP^nRc_r{&1 76{q\D/< m>Z+JDÞČtfIWT zt}\a{n8;mŽҵDV斋F m 6ZG ݯt;{:k1<"&BuzI IJ=,oI6)?Ο-H$|ZWtC4-N)컨Z4aJt+BͺmtueHh\{ŭ駾EO|c$T>/ik2ɳh޴{~m~ ~⿦$z 3jVlyZ5Vl V{5??9QGzT}5!Vwm^0~HMZͫ<ZZ8}v * fF5m[J1zcK)]HR̄j=S~ɣm;WFI_.ow4-Zƹ:f[:P ;iCkmCΡ\)9"e湆-$%Ҭ6[RnsWq%bOz]ڜnV Xax#4ybZQZ {9cMiڢ)6-:T;l&^O~oj)xeIs*ڞ$םL^֭rHҴҌ`;;lxe+I$ 8H2TrgsB|aY" i%I OezLql2Zi[y^(asrœB$b=kk÷jf[CkZ xϔ(gZ_T7 GDm&ϧc|~@?B=Ul|~oU{5R7&koM?'Ag/Dà:n΢ vnBv]_j{,8ӓ^(ZM ւ)n8⡴Ap \۬Ws"a [ݺ9#ثk]z1bƆ+Iao"^5?]ϫ[Zx t?v*߶~'PWlR`Z]! 5qA8q ^*; F{ \J> ]goݎor~ G o]p.tt{^c nJ޷6Fr QɩO4:0fM M=5GG|/0ZwqqInj_}E/2uCKP@bx\}i)"ܞ%w2D^0ȑ4 uKנ+@#G$"mˈ2ݼߍB/[[?q!QE^1i0J  ONYwy֖t{aT1Ќ"jsMQf0Tql1 4OƳ!V>TA\i/r}Q=.?DiXs[B!zԌW( ˇ! mhI~//0ހOGh}"+Z$^ ά՗ cPa sxhR{xSꇧkb>khLG䒢fw"Moujv_tˎ̤n:GbQ[Qpb2#$7E)[m -to%qcnm6Va%mrG>UsksU⫽v0fCް,y:e#!*}|ƺb{Sp'H'c6`ڹ2]ލO78j6hHSYnHuO@c -m vBT՜-%ҞAZ|Oh67WBBXȾNs7SMnw\ 8j_% :^J{O|**=⧾`px^MxoWj^=z=ɶObqZJYI t5**f eHq G^kI nD$myZmoa [ -Fue!iV^5([1@q(y9>RhM Qj 734k )o6n쵩>i[͡lhJ$y GC,amH+Vi hJ= R&`4n1^b" y-'ycנڰR5Ӣny 8 }.zkk-lqҬEpk{_NXCc~ϒ-7eX#ZSc|O^g촷=sQG">Ӿކ#UO=_לݔɲ1* y齉b6IiE橣^⑯?gT72!h4[ĶX!<7qTy+O7OOE )nۧ6@4oxkga=fx e_ooO 1vK%Ioy~@譯Yg!myh|~tvUqµ+0ڛPqΊ=jKk$ס+7l b\$<[ P MҷƩhfK*zUeOU=*T *Tq=~?XUW?z5]MxoY& RNm ӯ4䤅Gͽ5P +*ϕ\B˥w"-A:j$u+8ZsiԦ,.t8RU9H Zkzr EV64fh(7=PMĆYzC{$I]8I"̼̬̆8tYȢ\,DSm'25^q).JT)Kw`e5\S*ERXԿ֔ RP?}wQP!ҋ%)R@FeJZy7=Vko뺑h]js}Ci79X>OEgLVF.Nqm[&Ә\tycXZBS`}k]|l ggt;iU1۹sH:x(nbxƬm}ِV(XCxI6GBċQl'?ܩkB У71+sMzWQ|&SHT/wG0׶Lf>t_i_ 6TTܙ|/QcBc#L&0y*]5BfJ P鲇v؞!HP'շ3 ^+ :t'V!mJPL5k A&ªzF%:\+u-qISD6;bD8M8rVVt)'\(8VDxb(Zr ۣD|Tz&;LbF ϐuX( i Sا2wEsW`8n&iKkt,6M5<(JrHRBB=Ra\ϺḊ$rO"2.gnfD[N#Q=f7^vq -HlL2/TW)/jxӎLf~x?)ƽli R_J͡TMCl͏*VF"snEpl1i)zT<\JO^mj1جCc~r8Rok\+OY٭BVkj* ="AJ{O|**=⧾`px^MxoWj^=z=ɶ¦xbS-LH eg}FTlBԨkhkϠb[U*n7T`m97)G {c7G+RRp^NcG Jd-/Ң[AtW5aqۤ$mj7YG%YleJTҬOUXe4Ne'Z=tlV %0&[e) t;وJnAxԴɵe^=s13hxd:0횙h%N5_9jRWNUvpwh,ru=Mon9sOZ[jդNV3*ݜyhe9UYilC sRqDUr¬!H {,a:f!! -<.b`؜W/Sޙs#WPum5y.!jY5*c^g?Wn5楯m4Ҳ6.Ӊ{IOwIxOF(͠YnlkQMO@m3̴MhhFԥ*\7D65LNGy:)J{ǭ7/ĖRJl^Tیo twAH,u=íCuU6]뉳&Ӿ 5oax(#iҙm[fS-dP-clWIf[A6Jf=E<Ԫ*;t&kMsiF~-ʇ"Z!/*fW7Y3 m:l6[ڟ;aKڨnI#I̱ەjF,!N>$Է8S`!m- x5/flY.! h&`Jyn7q溽(wR oMMOʭCضYDƪ8fC6 -n!J*VSWGdFsuW< $q\R)@m%[+YaeS^c7<HOQU4W/d޲HdˉUJ, 'ŵdgD6󀔶oMaR܆[:+RGKt՛3o! qKlSp*IZ;lZC,hG~,0^q' srI$$buaq1/ /ssueVty"ւy$6.$4iB)I"m"w_(ܺ<9+\` \K;H!j uM%͈Jq%%n]sn,mf:eVEeƊs xdn6o8i=<(\)PJCT `thc*{aVU~~#=Rkǿ}TnMe1؄-l9g7Mr6g t2#ʌaqӛ2n<%t^k)bzuErz뱛34-5A{ٕetq/s2q$&KPIB.y)RH㓟{ۢeèrj8y*<[z,ۈĹKj4%LyLJRVi֞Ɵ ɲo[AIYiݔ/ek½,2 M]GUGFTMݼhhE +n(R[نcEwhKRCn2Z$+*HפZ'p2oS6/dM ,R Nv(@Xi2Ffnj zBTR(Ff̆':+ȶNWխUo472МL1ʜYm=(Y+P򀚪%Ĭq?M)6"ܧ~kBٍt>1[oyӕ?Zsm,Nn(p̯EO|C*Z?zE }1jȟ^WtȝZWt {_m/jGZWtțZWtvh[R,w>BJo{QSISDqVtOXQKJyNC^mAb!EZ򆕺Vdzh[s基CYTں|?+Iᾪ<1[V;qߑgN{Z58V;eSV3ӋM~l+ ă) &!$GKL# U*RCh)&5bqӅQv,dA%m} ӎ[,Mև3++m󂆇m>~ݽơ΄YR2ܦIhyߨՌs3;2T͔ rw)x{vB.Є t ֢x[7SٿZS9_\}'* L4)!;t~?ERgHH,݆z"wx#^F&U&HX#PoO/I3C)7G.WyXQ(bb694OϺ|JʠSӴ$t^QfHmo !eWyf|iBT1I@J[V]P~K$I>9IHӮgf5kYYU=iPWYlSd!*A1 NtZC1~rVb/xsq@I">m8qA#:.7*Yp-kdCxa%t爭UPf"lk1U%nwy JtHI@I{!CJy/rXs}u ֲJVĒ[\4u@RGg YaN-U9OOJRxXWǼT¬ I Rkǿ}G6Z*U̩R@=1MOMPFS_^.Cy֐Hzzjpҕ*S^}wUj1oUF!RTjN'܈?MgبlܼSX{)#羝|sמݛqi =G)l}$OBMl3iA0veO:ԖƒbCh`.Jy+C))r7KW='߷keK:+Km#2u^!ÓL98$29Ҕ]*Y+NoRS=ٻ#Qz ~?ZWU0OV3_EUM䟢~bOaj-|oG(=u [2J74ԥnQԕuCF57sSu?]Wġó|urk`u,P`b8ot&?NsT%CK9,yHaS)] kCwD6Rq0*Tj ЫUlpön.Sf:|N}ࡕ.?5>¹ml.mehd1\]NiwqnzK)MmUump0"WCqMH<-vg0M4ks,<I6P*9qķ"\m{Szu&61U6HQc”~,wjZKHQٗ"- 9xJdUKlJrKl-*%_`;_Khm+}[2MFbv=⧾`p_S 8 s\tۋԪ4KZTԨl`Ork4Q5*mszGqaS^1(>䆂/MVcdlxiA|O^.%GCokE/,_(G农^GRH"$_qG*|7#:t}EkݐyJ.h ?eP_$j+C)+$ۇR%?@Qinq5YeMDuIX $|ZOteݙv&+*KВm8n iIm +F&'g=;B6sZ P1ߟj}P5塣 8 &8y(="qm&rԭ!i )ֱ uz>4l(l]Ҕ'+} Yn#܎:]̫v(ø ہߺU6J<851Ȏ^IpJE쒝ֺ?\9cS WHIf'*n vFF^9s53 _!1I_9Vи`аINQY!^lHͬ,O nT>rܹehJ xzX,"A{z$Y%ŻYoٌ7/?7:즒v.T.xfW1l|IӮܖp4+@2a MoJq-Ga:^q^cUNuVĉĭ`ej VnA)MSM]H{/$er J uj:h pw_r:w/728 OM#`uK )5jگSJZT YNmu+A#>LOթ0y 㬟]_WN5p>jUg?}zgWiVp:IΰO+eĞ<ծM*cKcIxJh̎X0>L^>G.m.9{ի3jmh`H>hEoZ[P3.smk9q8tQV]m֒J A):J<}KZOz ҚrOW+P"̿t^z5HaF g=cIUñTTO W3,jJ in-ԕRdRAV5x̓M!(-X[6Fڡop+ec)̕~6== ZJ useɸ Fa&д%ř-֐!BT{͡ 8t)x[um"fc傾ABZ*B|I7%ZZ#bLC+ȥ!hp ?,hK-bo[Z#Nn~q8'Do4ZòɠsN~@mY5Wʋe* BPaR͓cԛ%kؚqQ[#&'X $M79Ai ޳d}E5+_ Mf^rYQ$!RQNV sj~:& 1ޞHHޡKgzm(-k*IpH}Mha^^=Rr(Rԓ|Pt~OS0K:ҟmoiuN9V)+jy; ,$);rEGmd)8%$o 59 W+Dl6(ؙCwY͝@B sv[jD)-حZwh92N]'l&GיܺZAu(IiEiqJVlf(w ݇7b>z Ą/xS,SV}x8Q̯a>ԄjE3qZz5/WTRP==FR֕KM@ii)"GB:A-^VY>vyNգrnNakvE#ɱDJo$E+#P/^ˁ¢#}4*-"Bj"\MY,oYRXH*W_6CZ]"cZ6bFC A=^Z!wW gsmlr-dQC?kWžV j==F@RRת6/toq-zT1 ROĨrw&Dfz8zVծF5v򜾕!%=(}cmk[~ڸ8T3R(~>7['f8w]wNNrbgq-[ r㰥:BÉ!Y B1ȫֵm*7$Zb[1$k;)Wxs)&oPvYʑԨMc=v2^B'0LzZ=*?XUU|{O|*+OTn&{7۬{mk;KcЁ*B?q%~Az+GBv+ c';β k"moxGpRw@j~krTlrڪ!Qj2-'^uX 0H^mn)/%L|F4l 1 -Y$6.ʜ* qob**JI\IM~jݫ^ʗWm)dӝ:}+ ZܽB27u%&̉^U(mh ރp-%ܤ rfסsr2m7X:دg!ԼgaHSdGIU:VN=\ C6U0!'x lzN[k}kyHqhlݷYY ic*`m|kQq󏺹M .P6ԕY8(qP1eP+ *M7rS?*h/b{|eSwPUSoSc`lO(Ru uGJl@x-eZ4oZMތO] yK.P9*1/i̵F2jǧRNx^Ep?MzX }5Y&Ƿ@m 1b.gƌd9@V [$| ϩŔs'zғk a-eɵ %%JUAo`4]\Oc8Nf;RӫZӷAԌoBb5_/nH SQ^NM.s%e%< d%M0:Ku/ J=z Xðf\Ґڳ7q֢d#JՖ]ʍRj-aZFp,z6rh堵J+݅?Nv=⧾`p_S 8 ZV6BPBEFy+W(!g~ݳi4I<4 , MaSʪYUP#JRzDmOOTOR#OOeR*= d%bǾ[֖%!c-lESN|I{ď*:eRTl ʑ}Ӆjcb0T߉om6Qf!a& FBfhp9R>Bo@ yzd4p˩R1@AEH/a~tːklЧwks;7D!^o>4'}U1͕c3Jj#|{Ո=JJ`qZ6JJ.:Rhawo;!sU85Ia['#kdpi69kKn5EYR|´0az>@kSPPiTJ"&ϑyGnjrFf47v:|O=pF (6gG5w9G2U+ ZB1W z.nVx {kP,Gcfn[y "%xm筞ZhϝH\m^m X~}ZK&dn2ܙ2Tnw!z* ;keNKGNYﶺع"Hi/4=( gsuA2"Lj^+y[uOkm!B{UmiP ǼT¬*{aV\GzcnMJMPӽirw4Wc2ӽirw4P.];.fN˾Jrپw4t|T.}3MfHҥ@lC}iRn[;fN˾Jrw4w]*T ˧{LӽiR\w].];.f*˧{LӽiR\w].];.f*˧{Lw4PDϞ?.f˾Jit|T;.fN˾Jrw4t|T.}3KN˾Jrw4t|T.}3KN˾Jt|\w]*T˧{LӽiR\w].];.f*˧{LӽiR\w].];.f*9*S-'Jkl8 T_ [8@8 NormalCJ_HaJmH sH tH FF Heading 17$8$@&H$CJ!OJQJ^JaJ!VV Heading 27$8$@&H$^`CJOJQJ^JaJNN Heading 3$<@&5CJOJQJ\^JaJBB Heading 4$<@&5CJ\aJ<A@< Default Paragraph FontO medium, @, Footer  !&)@!& Page Number,2, Header  ! \           #.3CN>V1Y \3bCS  6R(0j9FOR\fpdyINRUWY[]`bd C Kb'1E>LsX`krt,ydyJLMPQSTXZ\_acfgh 7,SqdyKOV^eU9V;V \C !!l,b$thMhnm #"@j(    S Ar http://www.nursece.com/onlinecourses/imagesPain/Fig2.gif"`B S  ? \ Tnr )mqnxY^  M X Z e   4 5 : M U W h @ A I     ) [ e g p u { Yav~%3vx?L?F"z :E\hY c f k l o *"3"###%% %&%%%%%7(;(--../////m0r011111.383q3t33444444 66666667 77p7t7~777728<899%:):::::B;F;m;v;;;Z<e<<<A=L===p>z>>>>>?? @@@!@K@O@i@s@v@w@@@@@@@@@AAAAAAABBgBkBlBnBBBBBCCCC%D-D4D>DDDDD E#EjEtEF FFFFF)I/IIIJJJJJJJJJJJJ K KKKKKKK LLLLLLPMTMZN`NcNiNjNvNOOO8PDA{3VB IM !7k TXC ȇ^$*!\A-6tJ wӊA-W%R21n$a*:^RM!,N .^W@d T1.,5 2)T_2g,~5Pj75dJO6?z`7\ dX70f"A?J@N4@zx<4D!,rKa>ML"z:rNKQV*tEQY\!al@a7bzVgb\@."d未Qe]Y4e2,Qkgl@"i &jJ7!SjnZj)Tt l~Jz#_l"g5pR}z5crd3sa}%YkuR21@w " sw;#yK] FT&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo  ^ `OJQJo(hH  ^ `OJQJo(hHxx^x`OJ QJ ^J o(hHoHH^H`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hHTT^T`OJ QJ ^J o(hHo$ $ ^$ `OJQJo(hH  ^ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHdd^d`OJQJo(hH44^4`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.^`OJQJo(hHTT^T`OJ QJ ^J o(hHo$ $ ^$ `OJQJo(hH  ^ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHdd^d`OJQJo(hH44^4`OJ QJ ^J o(hHo^`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH^`OJQJo(hHTT^T`OJ QJ ^J o(hHo$ $ ^$ `OJQJo(hH  ^ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHdd^d`OJQJo(hH44^4`OJ QJ ^J o(hHo^`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH8^`OJ QJ ^J o(hHo8^`OJ QJ ^J o(hHo8pp^p`OJQJo(hH8@ @ ^@ `OJQJo(hH8^`OJ QJ ^J o(hHo8^`OJQJo(hH8^`OJQJo(hH8^`OJ QJ ^J o(hHo8PP^P`OJQJo(hH8^`OJQJo(hH8^`OJ QJ ^J o(hHo8pp^p`OJQJo(hH8@ @ ^@ `OJQJo(hH8^`OJ QJ ^J o(hHo8^`OJQJo(hH8^`OJQJo(hH8^`OJ QJ ^J o(hHo8PP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH"^`B*OJ QJ ^J o(phhHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo  ^ `OJQJo(hH  ^ `OJQJo(hHxx^x`OJ QJ ^J o(hHoHH^H`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH8^`OJ QJ ^J o(hHo8^`OJ QJ ^J o(hHo8pp^p`OJQJo(hH8@ @ ^@ `OJQJo(hH8^`OJ QJ ^J o(hHo8^`OJQJo(hH8^`OJQJo(hH8^`OJ QJ ^J o(hHo8PP^P`OJQJo(hHh^`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHhh^h`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHpp^p`OJQJo(hH@ @ ^@ `OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH&88^8`B*CJOJQJaJo(phhH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH8@wN4@07k Zj5 2_20t l{3VO60kg!aW%0Qe>MLrK5craQVz:rN0;#yz`70 IM $a"A?3s2PI@."dC _l\~5b] dX7^$RM!A,N .4D4ej75A-"i &j"g5pw@wEQYgb!Sj0%Yku T1.0-6t8@NN X!X"X(X)X-X.X0X1j2j3555657_8_9p<p=@ACDyHyILMNOn[ \@@@@0@@@@@@&@P@@*@X@@2@h@@8@t@@<@|@@@@@@D@F@@@J@@@P@@@V@@@Z@@@`@@@f@h@j@@@x GzTimes New Roman5Symbol3& zArialQ& zMicrosoft Sans SerifW  Wide LatinEngravers MT?Wingdings 3;Wingdings9 Webdings?& Arial Black?5 zCourier New"1hqƇqƀݚO K & JN (!h0d/]\!Pharmacology Study Guide  Test 2 annelieseRNOh+'0  , H T ` lx"Pharmacology Study Guide Test 2oshar arararNormalo annelieseRN2neMicrosoft Word 8.0G@@r|@@ O K՜.+,D՜.+,L hp|  /&/]  "Pharmacology Study Guide Test 2 Title(RZ _PID_GUID _PID_HLINKSAN{4CE8E42F-B00B-4780-B82C-A18C4EB8360E}A pfr pns_sns_sf^C9http://www.nursece.com/onlinecourses/imagesPain/Fig2.gif  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz|}~      !"'Root Entry F1xyr)Data {=m1TableLWordDocument,SummaryInformation(DocumentSummaryInformation8CompObjj  FMicrosoft Word Document MSWordDocWord.Document.89q